Sleep Apnea Test at Home: How It Works, What It Measures, and What Your Results Mean
What Is a Home Sleep Apnea Test?
A home sleep apnea test (HSAT) is a portable diagnostic device that records breathing, oxygen levels, and other physiological signals while you sleep in your own bed. Unlike an in-lab polysomnography (PSG), which requires an overnight stay in a sleep center with technicians monitoring 16+ channels of data (EEG, EMG, EOG, ECG, airflow, respiratory effort, and more), a home test focuses on the signals most relevant to diagnosing obstructive sleep apnea (OSA): airflow disruption, blood oxygen saturation, and respiratory effort.
The concept isn't new. The American Academy of Sleep Medicine (AASM) published its first clinical guidelines for portable monitoring in 2007, establishing that unattended home devices could diagnose OSA in patients with a high pretest probability of moderate-to-severe disease (Collop et al., J Clin Sleep Med, 2007; PMID 18198809). The 2017 AASM Clinical Practice Guideline reaffirmed and strengthened this position, giving a STRONG recommendation that either polysomnography or home sleep apnea testing with a technically adequate device be used for diagnosis in uncomplicated adult patients presenting with signs and symptoms of increased risk for moderate-to-severe OSA (Kapur et al., J Clin Sleep Med, 2017; PMID 28162150).
The clinical bar is clear: home testing works for straightforward cases of suspected OSA. It does not replace in-lab testing for patients with significant heart or lung disease, neuromuscular conditions, chronic opioid use, or suspected central sleep apnea (though newer devices are expanding those boundaries).
How a Home Sleep Apnea Test Works: PAT, Oximetry, and Actigraphy
Not all home sleep tests work the same way. Traditional portable monitors (Type III devices) record airflow through a nasal cannula, respiratory effort with chest and abdominal belts, and oxygen saturation via pulse oximetry. These are miniaturized versions of the sensors used in sleep labs, and they work well, but they can be cumbersome to self-apply at home.
A newer approach uses peripheral arterial tonometry (PAT), a technology that detects breathing disturbances by measuring changes in finger blood vessel tone. During a normal breathing event, sympathetic nervous system activation causes vasoconstriction in the fingertip arteries. During an apnea or hypopnea, the body's autonomic response creates characteristic patterns of vascular tone change, heart rate variation, and oxygen desaturation that the device can identify and score. The WatchPAT ONE Sleep Apnea Test uses this PAT-based approach, combining a finger-mounted sensor (measuring arterial tone, oxygen saturation, and heart rate) with a wrist-worn actigraphy unit that tracks body position, movement, and snoring.
A 2013 meta-analysis by Yalamanchali et al. pooled 14 validation studies (909 patients total) comparing PAT-based portable devices with simultaneous in-lab polysomnography. The overall correlation between PAT-derived respiratory disturbance index (RDI) and AHI values and PSG-derived values was 0.889 (95% CI, 0.862-0.911). For AHI specifically, the correlation was 0.893. For the oxygen desaturation index (ODI), it was 0.942. Thirteen of the 14 studies used blinded designs, with PAT and PSG recorded simultaneously (Yalamanchali et al., JAMA Otolaryngol Head Neck Surg, 2013; PMID 24158564).
A 2023 systematic review by Moffa et al. examined 18 WatchPAT validation studies totaling 1,049 patients. Across studies, sensitivity for OSA diagnosis ranged from 87% to 96%, and specificity ranged from 66% to 80%. The review concluded that the WatchPAT represents "an effective and convenient tool for OSA diagnosis compared to standard reference systems" (Moffa et al., Sleep Breath, 2023; PMID 36036338).
At-Home vs. In-Lab Sleep Study: What the Evidence Shows
The gold standard for diagnosing sleep apnea remains in-lab polysomnography (PSG). A technician applies sensors, monitors your sleep in real time, and a sleep specialist scores every respiratory event by hand. It's thorough. It's also expensive, inconvenient, and for many people, the unfamiliar environment leads to atypical sleep.
A 2006 meta-analysis by Ghegan et al. compared home and laboratory sleep studies across 18 prospective studies. Key findings: respiratory disturbance index values on home tests were about 10% lower on average compared to lab studies (OR 0.90, 95% CI 0.87-0.92), meaning home tests slightly underestimate severity. There was no significant difference in mean oxygen saturation readings. Recorded sleep time was 13% higher in the lab (likely because technicians can verify sleep onset, while home devices estimate it). Home studies had a higher rate of technically inadequate recordings, but cost 35% to 88% less than lab studies across multiple countries (Ghegan et al., Laryngoscope, 2006; PMID 16735890).
The Gottlieb and Punjabi 2020 JAMA review, which synthesized data from multiple trials and cohort studies, reported that home sleep apnea testing has a sensitivity of approximately 80% for diagnosing OSA. The review also noted that OSA affects roughly 17% of women and 34% of men in the United States, making it one of the most common yet underdiagnosed conditions in adult medicine (Gottlieb & Punjabi, JAMA, 2020; PMID 32286648).
The practical bottom line: home testing catches most cases of moderate-to-severe OSA. Where it can miss is in mild cases (AHI 5-15), because the slight underestimation effect can push a borderline result below the diagnostic threshold. The AASM guidelines address this directly: if a home test is negative but clinical suspicion remains high, follow up with an in-lab PSG (Kapur et al., 2017; PMID 28162150).
Who Qualifies for Home Sleep Apnea Testing
The AASM guidelines are specific about who should and shouldn't use home testing. Good candidates include adults with signs and symptoms suggesting moderate-to-severe OSA: loud, habitual snoring; witnessed apneas (a bed partner reports that you stop breathing); excessive daytime sleepiness; and morning headaches. Obesity (BMI over 30), large neck circumference (over 17 inches in men, 16 inches in women), and crowded upper airway anatomy are additional risk factors that raise pretest probability.
Home testing is NOT recommended for patients with: significant cardiopulmonary disease (heart failure, COPD, pulmonary hypertension), neuromuscular conditions that could cause respiratory muscle weakness, chronic opioid use, history of stroke, suspected central sleep apnea, or severe insomnia. These conditions can either degrade the accuracy of home monitors or indicate the need for a more comprehensive sleep evaluation that only in-lab PSG can provide (Kapur et al., J Clin Sleep Med, 2017; PMID 28162150).
The Pillar et al. 2020 multicenter validation study (84 patients across 11 sleep centers) showed that the WatchPAT can now also differentiate between central and obstructive sleep apnea, achieving a sensitivity of 67% and specificity of 100% for central sleep apnea detection at an AHI threshold of 15 or greater (Pillar et al., Sleep Breath, 2020; PMID 31402439). This is an evolving area, but it suggests the technology is advancing beyond its original obstructive-only limitations.
How to Interpret Your AHI Score
The apnea-hypopnea index (AHI) is the primary metric from any sleep study, home or in-lab. It counts the average number of apneas (complete breathing cessation for 10+ seconds) and hypopneas (partial airflow reduction with associated oxygen desaturation or arousal) per hour of sleep. The AASM classifies OSA severity as follows: Normal is an AHI below 5 events per hour. Mild OSA is an AHI of 5-14 events per hour. Moderate OSA is 15-29 events per hour. Severe OSA is 30 or more events per hour.
These cutoffs aren't arbitrary. The Wisconsin Sleep Cohort Study, a landmark population-based investigation that began in 1988, used polysomnography in 602 randomly selected employed adults aged 30-60. The study found that 24% of men and 9% of women had an AHI of 5 or greater. When they added the requirement of daytime sleepiness to the criteria, 4% of men and 2% of women met diagnostic criteria for sleep apnea syndrome (Young et al., N Engl J Med, 1993; PMID 8464434).
Updated prevalence estimates from the same cohort, published by Peppard et al. in 2013 using 1,520 participants aged 30-70, showed the problem has gotten worse. Moderate-to-severe sleep-disordered breathing (AHI of 15 or greater) was found in 10% of men aged 30-49, 17% of men aged 50-70, 3% of women aged 30-49, and 9% of women aged 50-70. The relative increase from earlier estimates ranged from 14% to 55% depending on subgroup, driven largely by rising obesity rates (Peppard et al., Am J Epidemiol, 2013; PMID 23589584).
Globally, Benjafield et al. estimated that 936 million adults aged 30-69 have mild-to-severe OSA (AHI of 5 or greater), and 425 million have moderate-to-severe OSA (AHI of 15 or greater). In some countries, prevalence exceeds 50% of the adult population (Benjafield et al., Lancet Respir Med, 2019; PMID 31300334).
What to Do If You're Diagnosed with Sleep Apnea
A positive sleep apnea test should prompt a conversation with a sleep medicine specialist. Treatment depends on severity, symptoms, and individual factors. The cornerstone treatments are: Continuous positive airway pressure (CPAP), which uses a mask to deliver pressurized air that keeps the airway open during sleep. It remains the first-line treatment for moderate-to-severe OSA. Oral appliances (mandibular advancement devices), which hold the jaw forward to prevent airway collapse, are effective for mild-to-moderate OSA and for patients who can't tolerate CPAP. Weight loss and exercise, which directly reduce OSA severity (a 10% weight loss can reduce AHI by 26-50% in many patients). Positional therapy for patients whose apnea is significantly worse when sleeping on their back.
The stakes of leaving sleep apnea untreated are well documented. Marin et al. followed 1,651 men for an average of 10.1 years in an observational study. Patients with untreated severe OSA had significantly higher rates of fatal cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 per 100 person-years) compared to healthy controls (0.30 and 0.45, respectively). In multivariate analysis adjusted for confounders, untreated severe OSA nearly tripled the risk of fatal cardiovascular events (OR 2.87, 95% CI 1.17-7.51) and non-fatal events (OR 3.17, 95% CI 1.12-7.51). Patients treated with CPAP had event rates comparable to healthy controls (Marin et al., Lancet, 2005; PMID 15781100).
Beyond cardiovascular risk, untreated OSA is associated with a 2-to-3-fold increased risk of motor vehicle accidents (due to daytime sleepiness), impaired glucose metabolism, and cognitive decline. The Gottlieb and Punjabi JAMA review noted that excessive sleepiness is reported by only 15% to 50% of people with OSA in the general population, meaning the majority of affected individuals may not realize the severity of their condition (Gottlieb & Punjabi, JAMA, 2020; PMID 32286648).
Cost: Home Sleep Testing vs. In-Lab Sleep Study
Cost is one of the primary reasons home sleep testing has gained traction. An in-lab polysomnography typically costs between $1,000 and $3,000 in the United States (and can exceed $5,000 at some facilities), depending on geographic location, facility type, and whether a split-night study or two-night protocol is required. That's before any follow-up visits or titration studies.
Home sleep apnea tests are dramatically cheaper. The WatchPAT ONE Sleep Apnea Test is available through Instalab for $149, which includes the device, a physician review of your results, and a detailed report with your AHI score and severity classification. The Ghegan meta-analysis found that home studies cost 35% to 88% less than lab studies across multiple countries (Ghegan et al., Laryngoscope, 2006; PMID 16735890). In the US specifically, the price difference often represents savings of $1,000 or more per patient.
Insurance coverage varies. Many insurers now cover home sleep testing for patients who meet clinical criteria, and the lower cost makes it accessible even for those paying out of pocket. Given that most people with sleep apnea remain undiagnosed, the accessibility of affordable home testing is a meaningful step toward closing that gap.
Limitations of Home Sleep Apnea Testing
Home testing has real limitations, and being upfront about them matters for making an informed decision. First, home tests tend to slightly underestimate AHI compared to in-lab PSG. The Ghegan meta-analysis showed RDI values averaging about 10% lower on home devices (PMID 16735890). This means someone with mild sleep apnea might receive a normal result on a home test. The AASM addresses this by recommending that negative home tests in high-suspicion patients be followed by in-lab PSG.
Second, most home devices cannot distinguish between obstructive and central sleep apnea with the same reliability as in-lab PSG. The WatchPAT has made progress here (Pillar et al., PMID 31402439), but central sleep apnea detection remains more reliable with full polysomnography. Third, home tests have a higher rate of technically inadequate studies. Self-application of sensors means more room for error: a probe that slips off, a signal that drops out, a night of especially poor sleep. When this happens, the test needs to be repeated or an in-lab study becomes necessary.
Fourth, the Kinoshita et al. 2018 study (61 patients) found that arterial stiffness can affect WatchPAT accuracy. In patients with high pulse wave velocity (a marker of stiff arteries), the correlation between WatchPAT AHI and PSG AHI dropped from 0.78 to 0.40. This is worth noting for older patients or those with significant atherosclerosis (Kinoshita et al., J Clin Sleep Med, 2018; PMID 29458701).
Finally, home tests don't measure everything a sleep lab does. They can't assess sleep architecture in the same detail (though PAT-based devices do estimate sleep stages), can't detect periodic limb movements reliably, and can't identify other sleep disorders like narcolepsy or parasomnias. If your clinician suspects something beyond straightforward obstructive sleep apnea, in-lab PSG remains the right choice.